- Home
- ENSC vs CERO Comparison
ENSC vs CERO Comparison
Compare ENSC & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- CERO
- Stock Information
- Founded
- ENSC 2003
- CERO 2017
- Country
- ENSC United States
- CERO United States
- Employees
- ENSC N/A
- CERO N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- ENSC Health Care
- CERO
- Exchange
- ENSC Nasdaq
- CERO Nasdaq
- Market Cap
- ENSC 6.4M
- CERO 5.6M
- IPO Year
- ENSC N/A
- CERO N/A
- Fundamental
- Price
- ENSC $2.10
- CERO $5.52
- Analyst Decision
- ENSC
- CERO Strong Buy
- Analyst Count
- ENSC 0
- CERO 2
- Target Price
- ENSC N/A
- CERO $45.00
- AVG Volume (30 Days)
- ENSC 54.6K
- CERO 305.9K
- Earning Date
- ENSC 11-11-2025
- CERO 08-22-2025
- Dividend Yield
- ENSC N/A
- CERO N/A
- EPS Growth
- ENSC N/A
- CERO N/A
- EPS
- ENSC N/A
- CERO N/A
- Revenue
- ENSC $7,413,722.00
- CERO N/A
- Revenue This Year
- ENSC N/A
- CERO N/A
- Revenue Next Year
- ENSC $1,354.55
- CERO N/A
- P/E Ratio
- ENSC N/A
- CERO N/A
- Revenue Growth
- ENSC 415.58
- CERO N/A
- 52 Week Low
- ENSC $1.62
- CERO $4.27
- 52 Week High
- ENSC $14.67
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ENSC 48.61
- CERO 34.97
- Support Level
- ENSC $2.02
- CERO $5.29
- Resistance Level
- ENSC $2.19
- CERO $5.65
- Average True Range (ATR)
- ENSC 0.10
- CERO 0.53
- MACD
- ENSC 0.00
- CERO -0.07
- Stochastic Oscillator
- ENSC 41.45
- CERO 34.19
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.